Advertisement
UK markets close in 5 hours 48 minutes

  • FTSE 100

    8,396.07
    -28.13 (-0.33%)
     

  • FTSE 250

    20,785.22
    -88.11 (-0.42%)
     

  • AIM

    807.48
    -2.46 (-0.30%)
     

  • GBP/EUR

    1.1696
    -0.0002 (-0.02%)
     

  • GBP/USD

    1.2715
    +0.0009 (+0.07%)
     

  • Bitcoin GBP

    55,790.58
    +3,179.41 (+6.04%)
     

  • CMC Crypto 200

    1,525.99
    +37.45 (+2.52%)
     

  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     

  • DOW

    39,806.77
    -196.82 (-0.49%)
     

  • CRUDE OIL

    79.11
    -0.69 (-0.86%)
     

  • GOLD FUTURES

    2,421.50
    -17.00 (-0.70%)
     

  • NIKKEI 225

    38,946.93
    -122.75 (-0.31%)
     

  • HANG SENG

    19,220.62
    -415.60 (-2.12%)
     

  • DAX

    18,685.66
    -83.30 (-0.44%)
     

  • CAC 40

    8,131.64
    -64.32 (-0.78%)
     
Money:

What pension research reveals about retirement planning

As the cost of living crisis eases, what steps are you taking to build your pension?

CareDx to Report First Quarter 2024 Financial Results

Business Wire
·1-min read

BRISBANE, Calif., April 29, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-343-4136 for domestic callers or 1-203-518-9843 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240429253843/en/

Contacts

CareDx, Inc.
Investor Relations
Greg Chodaczek
investor@caredx.com